ATM Inhibitor-7
ATM Inhibitor-7 is a potent and selective ataxia-telangiectasia mutated (ATM) inhibitor with an IC50 value of 1.0 nM. ATM Inhibitor-7 induces Apoptosis and cell cycle arrest at G2/M phase when combinanted with CPT-11 (HY-16562). ATM Inhibitor-7 combines with CPT-11 shows antitumor activity.
For research use only. We do not sell to patients.
- CAS No.: 3033712-80-7
- Formula: C27H28N6O
- Molecular Weight:452.55
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
ATM 1.0 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
0.057 μM
Compound: 8d; A011
|
Anticancer activity against human HCT-116 cells assessed as reduction in cell viability by measuring CPT-11 IC50 at 100 nM incubated for 5 days by MTT assay
Anticancer activity against human HCT-116 cells assessed as reduction in cell viability by measuring CPT-11 IC50 at 100 nM incubated for 5 days by MTT assay
|
[PMID: 37312863] |
| HCT-116 | IC50 |
0.17 μM
Compound: 8d; A011
|
Anticancer activity against human HCT-116 cells assessed as reduction in cell viability by measuring CPT-11 IC50 at 30 nM incubated for 5 days by MTT assay
Anticancer activity against human HCT-116 cells assessed as reduction in cell viability by measuring CPT-11 IC50 at 30 nM incubated for 5 days by MTT assay
|
[PMID: 37312863] |
| HCT-116 | IC50 |
0.26 μM
Compound: 8d; A011
|
Anticancer activity against human HCT-116 cells assessed as reduction in cell viability by measuring CPT-11 IC50 at 10 nM incubated for 5 days by MTT assay
Anticancer activity against human HCT-116 cells assessed as reduction in cell viability by measuring CPT-11 IC50 at 10 nM incubated for 5 days by MTT assay
|
[PMID: 37312863] |
| SW-620 | IC50 |
0.032 μM
Compound: 8d; A011
|
Anticancer activity against human SW620 cells assessed as reduction in cell viability by measuring CPT-11 IC50 at 100 nM incubated for 5 days by MTT assay
Anticancer activity against human SW620 cells assessed as reduction in cell viability by measuring CPT-11 IC50 at 100 nM incubated for 5 days by MTT assay
|
[PMID: 37312863] |
| SW-620 | IC50 |
0.054 nM
Compound: 8d; A011
|
Anticancer activity against human SW620 cells assessed as reduction in cell viability by measuring CPT-11 IC50 at 30 nM incubated for 5 days by MTT assay
Anticancer activity against human SW620 cells assessed as reduction in cell viability by measuring CPT-11 IC50 at 30 nM incubated for 5 days by MTT assay
|
[PMID: 37312863] |
| SW-620 | IC50 |
0.076 nM
Compound: 8d; A011
|
Anticancer activity against human SW620 cells assessed as reduction in cell viability by measuring CPT-11 IC50 at 10 nM incubated for 5 days by MTT assay
Anticancer activity against human SW620 cells assessed as reduction in cell viability by measuring CPT-11 IC50 at 10 nM incubated for 5 days by MTT assay
|
[PMID: 37312863] |
ATM Inhibitor-7 (compound 8d) (10, 30, 100 nM; 5 days) increases the sensitivity of SW620 and HCT116 cells to CPT-11 (HY-16562) (100 nM)[1].
ATM Inhibitor-7 (0-100 nM; 24, 72 h) induces apoptosis and cell cycle arrest at G2/M phase when combinanted with CPT-11[1].
ATM Inhibitor-7 (3, 9, 27, 83, 250 nM) decreases the expression of p-ATM and p-Chk2 in a dose-dependent manner under 1.5 or 3 Gy irradiation conditions in SW620 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SW620, HCT116 cells
-
Concentration:10, 30, 100 nM
-
Incubation Time:5 days
-
Result:Increased the sensitivity of SW620 and HCT116 cells to CPT-11 (100 nM).
-
Cell Line:SW620, HCT116 cells
-
Concentration:0-100 nM
-
Incubation Time:24 h
-
Result:Dose-dependent increased in G2/M arrest was noted when A011 was combined with CPT-11 in SW620 and HCT116 cells.
-
Cell Line:SW620, HCT116 cells
-
Concentration:0-100 nM
-
Incubation Time:72 h
-
Result:Significantly increased the apoptotic cell populations when combined with CPT-11.
-
Cell Line:SW620, HCT116 cells
-
Concentration:3, 10, 30 nM
-
Incubation Time:24 h
-
Result:Reduced the expression of p-Chk2 when combined with CPT-11.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female nude mice (SW620 tumor xenograft model)[1]
-
Dosage:5 mg/kg; CPT-11 (5 mg/kg, i.p.; once a week)
-
Administration:I.p.; once daily for 23 days
-
Result:Increased the antitumor activity of CPT-11.
Chemical Information
-
CAS No. 3033712-80-7
-
Molecular Weight 452.55
-
Formula C27H28N6O
-
SMILES
CN(C)CCCOC1=NC=C(C2=CC=C(N=CC3=C4N([C@H](C)C5=CC=CC=C5)N=N3)C4=C2)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
ATM Inhibitor-7 Related Classifications
HY-149291 Related Classifications
Powered by Bioz